NEW YORK (GenomeWeb) – Dicerna Pharmaceuticals last week reported its third-quarter financial results, posting higher losses amid increased spending on its drug-development programs.
Dicerna's net loss for the period rose to $11.2 million from $4.5 million the year before.
Meanwhile, research and development costs climbed to $7.5 million from $2.4 million, reflecting the initiation of clinical testing of its Phase I cancer drug DCR-MYC and preparations to advance the preclinical primary hyperoxaluria 1 treatment DCR-PH1 into human trials.
General and administrative expenses rose to $3.7 million from $1.3 million, in part due to the costs associated with operating as a public company following Dicerna's initial public offering earlier this year.
At the end of the quarter, Dicerna had cash, cash equivalents, and held-to-maturity investments totaling $111.9 million.